$23.10
4.62% yesterday
Nasdaq, May 15, 10:16 pm CET
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Tonix Pharmaceuticals Holding Corp. Stock price

$23.10
+6.10 35.88% 1M
+9.99 76.20% 6M
-9.88 29.96% YTD
-561.22 96.05% 1Y
-57,832.90 99.96% 3Y
-444,200.90 99.99% 5Y
-4,063,999,976.90 100.00% 10Y
Nasdaq, Closing price Thu, May 15 2025
+1.02 4.62%
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Key metrics

Market capitalization $169.20m
Enterprise Value $38.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.79
P/S ratio (TTM) P/S ratio 16.85
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth -2.04%
Revenue (TTM) Revenue $10.04m
EBIT (operating result TTM) EBIT $-72.45m
Free Cash Flow (TTM) Free Cash Flow $-60.17m
Cash position $131.72m
EPS (TTM) EPS $-32.12
P/S forward 15.24
EV/Sales forward 3.43
Short interest 14.19%
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

Buy
100%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
10 10
2% 2%
100%
- Direct Costs 9.74 9.74
11% 11%
97%
0.30 0.30
141% 141%
3%
- Selling and Administrative Expenses 36 36
29% 29%
354%
- Research and Development Expense 35 35
53% 53%
344%
-70 -70
31% 31%
-695%
- Depreciation and Amortization 2.69 2.69
41% 41%
27%
EBIT (Operating Income) EBIT -72 -72
32% 32%
-722%
Net Profit -132 -132
34% 34%
-1,314%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
2 days ago
Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene
Neutral
GlobeNewsWire
4 days ago
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years
Neutral
GlobeNewsWire
17 days ago
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today